Approach to the Medical Treatment of Epilepsy

耐受性 医学 癫痫 重症监护医学 临床试验 不利影响 药理学 精神科 内科学
作者
Francesco Brigo,Anthony G Marson
出处
期刊:Continuum [Ovid Technologies (Wolters Kluwer)]
卷期号:28 (2): 483-499 被引量:4
标识
DOI:10.1212/con.0000000000001081
摘要

ABSTRACT PURPOSE OF REVIEW This article discusses the use of antiseizure medications in the treatment of focal and generalized epilepsies using an evidence-based approach. RECENT FINDINGS In recent years, several new antiseizure medications with differing mechanisms of action have been introduced in clinical practice, and their efficacy and safety has been evaluated in randomized controlled clinical trials. Currently, all antiseizure medications can prevent seizure occurrence, but they have no proven disease-modifying or antiepileptogenic effects in humans. The choice of therapy should integrate the best available evidence of efficacy, tolerability, and effectiveness derived from clinical trials with other pharmacologic considerations, the clinical expertise of the treating physicians, and patient values and preferences. After the failure of a first antiseizure medication, inadequate evidence is available to inform policy. An alternative monotherapy (especially if the failure is because of adverse effects) or a dual therapy (especially if failure is because of inadequate seizure control) can be used. SUMMARY Currently, several antiseizure medications are available for the treatment of focal or generalized epilepsies. They differ in mechanisms of action, frequency of administration, and pharmacologic properties, with a consequent risk of pharmacokinetic interactions. Major unmet needs remain in epilepsy treatment. A substantial proportion of patients with epilepsy continue to experience seizures despite two or more antiseizure medications, with a negative impact on quality of life. Therefore, more antiseizure medications that could provide higher seizure control with good tolerability and that could positively affect the underlying disease are needed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
WR完成签到,获得积分10
3秒前
不以为念完成签到 ,获得积分10
3秒前
onethree完成签到 ,获得积分10
5秒前
小饼干完成签到,获得积分10
5秒前
寻风完成签到,获得积分10
6秒前
阳光完成签到,获得积分10
8秒前
浑灵安完成签到 ,获得积分10
10秒前
坚定的海露完成签到,获得积分10
10秒前
12秒前
HEIKU应助科研通管家采纳,获得10
14秒前
Lucas应助科研通管家采纳,获得10
14秒前
SciGPT应助科研通管家采纳,获得10
14秒前
丁丁丁完成签到,获得积分20
14秒前
深情安青应助科研通管家采纳,获得10
14秒前
科研通AI2S应助科研通管家采纳,获得10
14秒前
今后应助科研通管家采纳,获得10
14秒前
彭于晏应助科研通管家采纳,获得10
14秒前
田様应助科研通管家采纳,获得10
14秒前
坚强亦丝应助科研通管家采纳,获得10
15秒前
研友_VZG7GZ应助科研通管家采纳,获得10
15秒前
完美世界应助科研通管家采纳,获得10
15秒前
大个应助科研通管家采纳,获得10
15秒前
大模型应助科研通管家采纳,获得10
15秒前
萧水白应助科研通管家采纳,获得10
15秒前
csy应助科研通管家采纳,获得20
15秒前
wanci应助科研通管家采纳,获得10
15秒前
坚强亦丝应助科研通管家采纳,获得10
15秒前
15秒前
15秒前
三号技师完成签到,获得积分10
17秒前
playgirl02发布了新的文献求助10
18秒前
小美爱科研完成签到,获得积分10
18秒前
王先生完成签到 ,获得积分10
20秒前
可靠的寒风完成签到,获得积分20
21秒前
Hello应助WR采纳,获得10
22秒前
李小政完成签到,获得积分10
23秒前
秋半梦完成签到,获得积分10
24秒前
25秒前
彭于晏应助zzzzz采纳,获得10
25秒前
12完成签到,获得积分10
29秒前
高分求助中
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
Die Gottesanbeterin: Mantis religiosa: 656 400
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3165024
求助须知:如何正确求助?哪些是违规求助? 2816112
关于积分的说明 7911373
捐赠科研通 2475753
什么是DOI,文献DOI怎么找? 1318362
科研通“疑难数据库(出版商)”最低求助积分说明 632098
版权声明 602370